How much do peptides cost?

"How much do peptides cost" doesn't have one answer, because "peptides" covers two completely different purchases: an unregulated chemical shipped to your door, or a supervised course of treatment through a clinician. The prices aren't even in the same category, and neither is what you're actually paying for.

What a "research use only" vial costs

On the cheap end, some overseas sellers ship peptide vials to U.S. buyers for "as little as $5 a vial," according to CNN's reporting on the unregulated peptide market.² More established online storefronts price individual vials higher: the Associated Press reported that "online stores will offer injectable vials for $300 to $600 each" for popular unapproved peptides.¹ Some sites bundle a nominal "consult" fee, as low as roughly $99, with the vials shipped directly afterward and no prescription actually required.²

None of that price includes a pharmacy, a clinician who can decline to prescribe, or any testing of what's actually in the vial. That's not a bargain. It's the absence of the parts of the transaction that would normally cost money.

What a licensed clinic or telehealth provider costs

Reporting on the wellness-clinic side of the market gives a clearer picture of what supervised peptide therapy actually costs. The AP found that "longevity and wellness clinics offer in-office evaluations and injections, sometimes with membership fees of thousands of dollars per month."¹ A more granular example: the San Antonio Report found that at one concierge clinic, "peptide injections generally fall somewhere between $300 to $550 per month, depending on the peptide and dose."³

Figures as reported by the Associated Press, CNN, and the San Antonio Report; not a quote or estimate from ArePeptidesGood.com. Actual pricing varies by clinic, peptide, and dose and isn't standardized industry-wide.

"These influencers are often advocating taking a stack of peptides each month, so it could be two, three, four different peptides. This is really what I consider dangerous."

— Dr. Eric Topol, Director, Scripps Research Translational Institute, quoted by the Associated Press (November 2025)¹

Stacking multiple peptides multiplies both the cost and the risk, whichever channel they come from. That's a separate decision from where you source a single peptide, and it's one worth raising directly with a clinician rather than a forum.

GLP-1 peptides: a market in transition, and what it means for price

The U.S. peptide therapeutics sector — spanning approved drugs, clinical formulations, and the wellness segment — was projected at roughly $52.6 billion in 2025 and growing at approximately 9 percent annually, driven almost entirely by GLP-1 metabolic drugs rather than the smaller wellness peptide market.⁷ That context matters for any cost comparison: the pricing dynamics of Ozempic and Wegovy are not the same as the pricing dynamics of BPC-157 or TB-500, but they share the same regulatory landscape and increasingly the same channels.

For most of 2022 through early 2025, semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) were on the FDA's official drug shortage list — a status that created a legal opening for compounding pharmacies to produce essentially-copy versions at a fraction of the brand-name price. That opening has now largely closed.

The FDA declared the national semaglutide shortage resolved on February 21, 2025, noting that it "confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand." Tirzepatide's shortage was declared resolved in December 2024.⁴ Once the shortage declarations ended, enforcement discretion for compounded copies wound down with them — 503A pharmacies lost their exemption for semaglutide in April 2025, and 503B outsourcing facilities in May 2025.

That regulatory shift is reflected in what GLP-1 therapy costs in 2026. These peptides now live in three distinct pricing tiers:

GLP-1 pricing changes frequently. These figures reflect 2026 published rates from licensed providers and should be verified directly. Compounded versions require a valid prescription from a licensed clinician and are not FDA-approved finished drug products.

The gap between compounded and brand-name has narrowed since manufacturers launched their own direct self-pay programs — but the compounded route remains the lowest cash price for most patients. The tradeoff is that compounded medications are not reviewed by the FDA for safety, effectiveness, or quality as finished products, and the regulatory window for large-scale compounding continues to tighten as shortages remain resolved.

What the FDA's regulatory tiers mean for what you pay

Peptides — short chains of amino acids — are a broad category, and the regulatory tier that applies to how they're sold is the single biggest driver of their price.

Research use only (RUO) vendors are not compounding pharmacies and are not regulated as pharmaceutical manufacturers. They sell peptide compounds labeled "not for human use," which exempts them from FDA pharmaceutical regulations. There is no requirement to verify purity, potency, or sterility. The FDA has specifically flagged numerous commonly sought wellness peptides — including BPC-157, CJC-1295, Ipamorelin acetate, GHRP-2, and GHRP-6 — as substances for which compounded drug products "may pose risk for immunogenicity" or for which the agency lacks "sufficient information to know whether the drug would cause harm if administered to humans."⁵ These are not obscure concerns; they are documented on the FDA's public list of bulk drug substances that may present significant safety risks. A cheap vial from an RUO vendor reflects the absence of every safety check that would otherwise drive the price up — not a better deal on the same product.

503A compounding pharmacies are state-licensed and must fill prescriptions for individual patients using pharmaceutical-grade ingredients. They operate under state pharmacy board oversight and must have a valid patient-specific prescription before dispensing. They are not FDA-registered as outsourcing facilities and do not undergo the same federal inspection regime, but they sit well above the RUO tier in regulatory accountability.

503B outsourcing facilities are the most tightly regulated compounding tier. They register voluntarily with the FDA, pay annual fees, and accept federal inspections on a risk-based schedule. The FDA maintains a publicly searchable list of all registered 503B facilities and documents each facility's inspection results, warning letters, and recalls.⁶ Products from 503B facilities carry a higher degree of quality assurance — and a price that reflects it. The fee structure, CGMP compliance costs, and federal inspection regime are real expenses that pass through to what you pay per vial.

Why insurance doesn't solve the cost problem

Most wellness-use peptides aren't covered by insurance — not because of a technicality, but because most of them aren't FDA-approved for the purposes they're marketed for. Weight loss, recovery, anti-aging, and performance are not approved indications for the peptides most commonly used for those purposes in wellness contexts. When a drug isn't approved for an indication, insurers generally don't cover it, and clinics bill patients directly out of pocket regardless of channel.

The exception that proves the rule: GLP-1 agonists like semaglutide and tirzepatide are FDA-approved for type 2 diabetes management, and some plans cover them for that indication. Coverage for weight loss specifically has been more limited and varies widely by plan. But for BPC-157, TB-500, CJC-1295, and the other wellness peptides popular in gym and biohacking circles, insurance coverage is essentially irrelevant — none of those are approved medications, so the question of what they cost is entirely a cash question.

That out-of-pocket reality is part of why cost comparison matters so much in this market — and why understanding what each price tier actually includes is the more useful starting point than shopping by sticker price alone.

Why the price gap exists (and why it's not the part to cut)

A licensed clinic's price is really paying for four things: a clinician's time, sometimes bloodwork, a licensed pharmacy's compounding and quality control, and follow-up. An online vendor's price is paying for exactly one thing: the chemical itself, unverified. When the price looks too low to include a pharmacy and a clinician, it's because it doesn't.

Insurance rarely helps here either way. Most wellness peptides aren't FDA-approved for the purposes they're marketed for (weight loss, recovery, anti-aging), so both the gray market and most licensed clinics bill out of pocket. That means cost is one of the few places you can compare providers directly, but it should never be the only variable, given what the cheaper option is actually missing.

For how to evaluate whether a provider charging clinic-level prices is actually operating like a clinic, see are peptide clinics legit? For the full breakdown of where to source peptides safely, see where to buy peptides safely.